ArticleActa pharmaceutica Sinica. B2026
Astragalus-derived nano-agonist potentiates chemotherapy by reducing tumor-suppressive macrophages.
Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based chemotherapy only achieves a short-term success in the treatment of triple-negative breast cancer (TNBC), which is attributed to immunosuppressive macrophages post-chemotherapy. Herein, inspired by the plant immune defense mechanism, we demonstrate that edible astragalus-derived exosome-like nanoparticles (ADNPs) exhibit conspicuous efficacy in reprogramming M1-like tumor-associated macrophages (TAMs) through the activation of TLR2 signaling. The docking between released formononetin and TLR2 plays a key role during the cell internalization process. As a result, ADNPs in combination with Cisplatin (termed ADNP-Cis) greatly inhibit TNBC murine tumor progression and metastasis. Besides, ADNPs alleviate the peripheral blood toxicity caused by cisplatin treatment, and show lower toxicity compared with other TLR2 agonists previously reported. Taken together, this safe and robust ADNP-Cis therapy offers fresh insights into the management of TNBC chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.